MedTrace Logo

Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer

NCT05746728 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2023-04-06

No results posted yet for this study

Summary

This is a multicenter, open-label, single-arm clinical study designed to evaluate the safety and efficacy of surufatinib combined with tislelizumab in the treatment of metastatic triple-negative breast cancer (TNBC). The study will be conducted in two parts; Safety lead-in phase and dose expansion phase.

Conditions

  • Metastatic Triple-negative Breast Cancer

Interventions

DRUG

Surufatinib

Safety run-in phase: 200-250mg, QD, Q3W Dose expansion phase: according to the dose determined in the safety run-in phase

DRUG

Tislelizumab

200mg, d1, iv, Q3W

Sponsors & Collaborators

  • Huihua Xiong

    lead OTHER

Principal Investigators

  • Huihua Xiong · Tongji Hospital Affiliated of Tongji Medical College Huazhong University of Science and Technology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-30
Primary Completion
2024-08-31
Completion
2025-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05746728 on ClinicalTrials.gov